NO20044865L - Karbonmonoksid som biomarkor og terapeutisk middel - Google Patents

Karbonmonoksid som biomarkor og terapeutisk middel

Info

Publication number
NO20044865L
NO20044865L NO20044865A NO20044865A NO20044865L NO 20044865 L NO20044865 L NO 20044865L NO 20044865 A NO20044865 A NO 20044865A NO 20044865 A NO20044865 A NO 20044865A NO 20044865 L NO20044865 L NO 20044865L
Authority
NO
Norway
Prior art keywords
disease
lung
cancer
biomarker
therapeutic agent
Prior art date
Application number
NO20044865A
Other languages
English (en)
Norwegian (no)
Inventor
Leo E Otterbein
Augustine M K Choi
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of NO20044865L publication Critical patent/NO20044865L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20044865A 2002-05-09 2004-11-09 Karbonmonoksid som biomarkor og terapeutisk middel NO20044865L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/014836 WO2003094932A1 (en) 2002-05-09 2002-05-09 Carbon monoxide as a biomarker and therapeutic agent

Publications (1)

Publication Number Publication Date
NO20044865L true NO20044865L (no) 2004-12-07

Family

ID=29418043

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044865A NO20044865L (no) 2002-05-09 2004-11-09 Karbonmonoksid som biomarkor og terapeutisk middel

Country Status (13)

Country Link
EP (1) EP1501523A4 (ru)
JP (1) JP2005532314A (ru)
KR (1) KR20040106515A (ru)
CN (1) CN1638781A (ru)
AU (1) AU2002308676B2 (ru)
BR (1) BR0215717A (ru)
CA (1) CA2484770A1 (ru)
EA (1) EA200401478A1 (ru)
MX (1) MXPA04011113A (ru)
NO (1) NO20044865L (ru)
RS (1) RS96904A (ru)
UA (1) UA84402C2 (ru)
WO (1) WO2003094932A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
AU2003208525B9 (en) 2002-02-04 2009-08-27 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Amend the invention title to read Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
MXPA04010243A (es) 2002-04-15 2005-07-05 Univ Pittsburgh Metodos para tratar ileo.
EP1499328B1 (en) 2002-04-15 2015-09-16 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods of treating necrotizing enterocolitis
WO2003096977A2 (en) * 2002-05-17 2003-11-27 Yale University Methods of treating hepatitis
JP2005345242A (ja) * 2004-06-02 2005-12-15 Tohoku Univ 肺癌の化学療法治療効果の評価方法
JPWO2007073005A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 メチル基転移反応調節物質
EP2099439A2 (en) * 2006-12-06 2009-09-16 Alfama - Investigação E Desenvolvimento De Produto Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
JP2010094122A (ja) 2008-06-12 2010-04-30 Keio Gijuku バイオマーカーとしてのマイクロｒｎａを用いた頭頸部腫瘍の診断・治療選択
JP2012046470A (ja) * 2010-08-30 2012-03-08 Japan Science & Technology Agency Ｇａｐｄｈの酵素活性阻害剤
CA2824056C (en) * 2011-01-14 2019-01-08 Children's Hospital Los Angeles Solution of carbon monoxide for treatment of disease, including sickle cell disease
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
US9359197B2 (en) 2011-03-24 2016-06-07 Technion Research & Development Foundation Ltd. Method of diagnosing, prognosing and monitoring parkinson's disease
EP2699242B1 (en) 2011-04-19 2017-11-01 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
EP2734235B1 (en) 2011-07-21 2017-03-22 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
US10031126B2 (en) 2013-04-04 2018-07-24 The Regents Of The University Of California System and method for utilizing exhaled breath for monitoring inflammatory states
EP2868348A1 (en) * 2013-11-04 2015-05-06 Universität Zürich CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair
TW201618795A (zh) * 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
JP7161737B2 (ja) * 2017-01-30 2022-10-27 哲也 石川 悪性腫瘍の検査方法
CN112236150A (zh) 2018-06-08 2021-01-15 住友精化株式会社 炎症性消化器官疾病用组合物
US20210228621A1 (en) * 2018-06-08 2021-07-29 Sumitomo Seika Chemicals Co., Ltd. Composition for skin wounds
US20220296636A1 (en) * 2019-06-06 2022-09-22 The General Hospital Corporation Carbon Monoxide as a Treatment for Neurodegenerative Disease
US20230346831A1 (en) * 2020-07-16 2023-11-02 Cornell University Methods for treating metastatic cancer using low dose carbon monoxide
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
JP2000517311A (ja) * 1996-08-27 2000-12-26 メッサー グリースハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング 水素含有薬剤
MXPA03008820A (es) * 2001-03-30 2004-07-30 Sangstat Medical Corp Compuestos generadores de monoxido de carbono, para el tratamiento de desordenes vasculares, inflamatorios e inmunologicos.

Also Published As

Publication number Publication date
MXPA04011113A (es) 2005-02-14
AU2002308676A1 (en) 2003-11-11
KR20040106515A (ko) 2004-12-17
EA200401478A1 (ru) 2005-12-29
WO2003094932A1 (en) 2003-11-20
EP1501523A4 (en) 2006-12-13
UA84402C2 (ru) 2008-10-27
AU2002308676B2 (en) 2009-06-11
BR0215717A (pt) 2005-02-22
EP1501523A1 (en) 2005-02-02
CN1638781A (zh) 2005-07-13
CA2484770A1 (en) 2003-11-20
JP2005532314A (ja) 2005-10-27
RS96904A (en) 2007-02-05

Similar Documents

Publication Publication Date Title
NO20044865L (no) Karbonmonoksid som biomarkor og terapeutisk middel
SE0200356D0 (sv) Novel use
NO20070994L (no) N-hydroksamid derivater og anvendelse derav
WO2003070188A3 (en) Method of treating trx mediated diseases
AU2002307494A1 (en) Human timp-1 antibodies
HK1123304A1 (en) Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
NO20054336L (no) Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer
IL178122A0 (en) Materials and methods for treating coagulation disorders
CA2444578A1 (en) Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
Li et al. TIMP-1 and MMP-9 expressions in COPD patients complicated with spontaneous pneumothorax and their correlations with treatment outcomes
DK1828160T3 (da) Cykliske sulfonylaminoderivater og anvendelse deraf som MMP-hæmmere
EA200200518A1 (ru) Способ и композиция для лечения заболеваний легких
WO2004045530A3 (en) Methods for treating, preventing, or reducing cardiac disorders using fadd inhibitors
HK1036054A1 (en) Substituted beta-diketones and their use
EP1661892A4 (en) CONDENS CYCLIC COMPOUND AND USE THEREOF
HK1115132A1 (en) N-hydroxyamide derivatives and use thereof n-
IL180681A0 (en) Pyridine derivatives, their preparation and use
San-Huang α-Macroglobulins: a modulator for growth factors
YU78800A (sh) Supstituisani beta-diketoni i njihova upotreba
WO2023173036A3 (en) Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease
ATE328120T1 (de) Bakterienstämme delftia acidovorans mc1-r, ihre herstellung sowie ihre verwendung zur produktion der r-enantiomeren von 2-phenoxypropionsäure- derivaten
UA88785C2 (en) N-hydroxyamide derivatives and use thereof
Green et al. Water for Life: The Impact of the Privatization of Water Services on Child Mortality.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application